Loading...

Financial Summary


InflaRx N.V.

InflaRx N.V. (IFRX)

Healthcare
Buy
B+
Market Info
Financial Info
Financial Modelling
Symbol IFRX
Price 2.69$
Beta -0.67
Volume Avrg. 0.07M
Market Cap 0.08B
Shares (2018) 28,844.83K
Last Div 0
Dividend Yield -
DCF Unlevered -
DCF Levered -
ROE -19.69% Sell
ROA -22.68% Sell
Operating Margin -Infinity% Strong Sell
Debt / Equity 0.00% Neutral
P/E - Neutral
P/B -

Income Statement

Download IFRX income statement Download IFRX income statement
Year 2015201620172018
Revenue ----
Cost of Revenue ----
Gross Profit ----
R&D Expenses 3.785.5617.3028.77
Sales, General and Administrative Expense 0.481.946.1714.70
Operating Expenses 4.117.5023.4743.47
Operating Income -4.11-7.50-23.47-43.47
Interest Expense 1.242.165.913.14
Earnings before Tax -5.34-9.41-29.10-34.27
Income Tax Expense ----
Net Income -5.34-9.41-29.10-34.27
Net Income - Non-Controlling int ----
Net Income - Discounted ops ----
Net Income Com -5.34-9.41-29.10-34.27
Preferred Dividends ----
Earnings Per Share Basic -2.28-4.00-3.12-1.37
Earnings Per Share Diluted -2.28-4.00-3.12-1.37
Weighted Average Shares Outstanding -2.4911.3028.84
Weighted Average Shares Outstanding (Diluted) -2.4911.3028.84
Dividend per Share ----
Gross Margin ----
EBITDA Margin ----
EBIT Margin ----
Profit Margin ----
Free Cash Flow margin ----
EBITDA -4.06-7.22-23.10-30.93
EBIT -4.10-7.25-23.19-31.13
Consolidated Income -5.34-9.41-29.10-34.27
Earnings Before Tax Margin ----
Net Profit Margin ----

Balance Sheet Statement

Download IFRX income statement Download IFRX income statement
Year 2015201620172018
Cash and cash equivalents 3.5930.65148.0063.66
Short-term investments ---116.30
Cash and short-term investments 3.5930.65148.00179.97
Receivables ----
Inventories ----
Property, Plant & Equipment Net 0.120.140.210.72
Goodwill and Intangible Assets 0.010.010.050.26
Long-term investments 0.000.000.020.24
Tax assets ----
Total non-current assets 22.5556.270.020.08
Total current assets 0.130.140.281.21
Total assets 3.8931.07149.12183.00
Payables 0.401.615.367.65
Short-term debt ----
Total current liabilities 0.471.845.728.91
Long-term debt ----
Total debt ----
Deferred revenue 0.020.02--
Tax Liabilities --0.000.36
Deposit Liabilities ----
Total non-current liabilities 22.5556.270.020.08
Total liabilities 23.0258.115.748.99
Other comprehensive income ----
Retained earnings (deficit) -19.67-28.48-61.58-93.23
Total shareholders equity -19.13-27.04143.37174.01
Investments 0.000.000.02116.54
Net Debt ----179.51
Other Assets ---1.12
Other Liabilities 0.070.220.361.26

Cash Flow Statement

Download IFRX income statement Download IFRX income statement
Year 2015201620172018
Depreciation & Amortization 0.040.030.090.20
Stock-based compensation 0.260.915.4613.89
Operating Cash Flow -3.59-5.25-14.59-27.26
Capital Expenditure -0.01-0.06-0.18-0.93
Acquisitions and disposals ----
Investment purchases and sales ---0.02-113.38
Investing Cash Flow ----
Insurance (repayment) of debt ----
Insurance (buybacks) of shares ----
Dividend payments ----
Financing Cash Flow -32.48130.6157.06
Effect of forex changes on cash 0.000.00-2.786.47
Net cash flow / Change in cash -3.6027.17113.04-78.04
Free Cash Flow -3.61-5.31-14.77-28.18
Net Cash/Marketcap ----

Retained Earning Schedule

Year 2015201620172018
Retained Earnings (Previous Year) --20-28-62
Net Income -5-9-29-34
Stock Dividends -141-43
Divident Paid ----
Retained Earnings -20-28-62-93
Year 2015201620172018
Gross PPE -000
Annual Depreciation 0001
Capital Expenditure -0-0-0-1
Net PPE 0001

Intangible and Goodwill Schedule

Year 2015201620172018
Intangible and Goodwill (Previous Year) -000
New Purchases ---0-113
Intangible and Goodwill 0000
InflaRx N.V.

InflaRx N.V. (IFRX)

2.69
-0.02 (-0.92%)

About


Niels Riedemann
Healthcare
Biotechnology
Nasdaq Global Select

InflaRx NV is a biopharmaceutical company. It discovers and develops potent and specific inhibitors of the complement activation factor known as C5a.